This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Landis, D. M. Articles by Loeb, L. A. Search for Related Content PubMed PubMed Citation Articles by Landis, D. M. Articles by Loeb, L. A.

Creation and Characterization of 5-Fluorodeoxyuridine-resistant Arg⁵⁰ Loop Mutants of Human Thymidylate Synthase¹

The Joseph Gottstein Memorial Cancer Research Laboratory, Departments of Pathology and Biochemistry, University of Washington School of Medicine, Seattle, Washington 98195-7705

Thymidylate synthase catalyzes the reductive methylation of dUMP to dTMP and is essential for the synthesis of DNA. Fluoropyrimidines, such as 5-fluorouracil (5-FU), are used extensively in cancer therapy. In the cell, 5-FU is metabolized to 5-fluoro-2'-deoxyuridine 5'-monophosphate, a tight binding covalent inhibitor of thymidylate synthase. Recent studies have identified 5-fluoro-2'-deoxyuridine (5-FdUR) and antifolate-resistant mutants of human thymidylate synthase (TS) that contain single residue substitutions within the highly conserved Arg⁵⁰-loop, which binds the pyrimidine substrate (Y. Tong et al., J. Biol. Chem. 273: 11611–11618, 1998). We have used random sequence mutagenesis to gain structure-function information about the TS and to create novel drug-resistant mutants for gene therapy. A library of 1.5 million mutants of the Arg⁵⁰-loop and the nearby residue Tyr 33 was selected to identify mutants of the human enzyme with the ability to complement a thymidylate synthase-deficient Escherichia coli strain and form colonies in the presence of 5-FdUR. E. coli-harboring plasmids that were encoding TS with single, double, and triple amino acid substitutions were identified that survive at dosages of 5-FdUR clearly lethal to E. coli harboring either wild-type thymidylate synthase or constructs encoding previously characterized drug resistant mutants. Four 5-FdUR-resistant mutants were purified to apparent homogeneity. Kinetic studies indicate that these enzymes are highly efficient. Inhibition constants (K_i) for the double mutant K47Q;D48E and the triple mutant D48E;T51S;G52C in the presence of 5-fluoro-2'-deoxyuridine 5'-monophosphate were determined to be 75 to 100 times higher, respectively, than that of the wild-type enzyme. These mutant TSs, or others similarly created and selected, could be used to protect bone marrow cells from the cytotoxic side effects of 5-FU chemotherapy.

This article has been cited by other articles:

				A. M. Fontes, B. M. Davis, L. P. Encell, K. Lingas, D. T. Covas, M. A. Zago, L. A. Loeb, A. E. Pegg, and S. L. Gerson Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells Mol. Cancer Ther., January 1, 2006; 5(1): 121 - 128. [Abstract] [Full Text] [PDF]

				H. Kawate, D. M. Landis, and L. A. Loeb Distribution of Mutations in Human Thymidylate Synthase Yielding Resistance to 5-Fluorodeoxyuridine J. Biol. Chem., September 20, 2002; 277(39): 36304 - 36311. [Abstract] [Full Text] [PDF]

				G. Gaspar, E. De Clercq, and J. Neyts Human Herpesvirus 8 Gene Encodes a Functional Thymidylate Synthase J. Virol., September 11, 2002; 76(20): 10530 - 10532. [Abstract] [Full Text] [PDF]